Allspring Global Investments Holdings LLC Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Allspring Global Investments Holdings LLC boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,013 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,931 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Jazz Pharmaceuticals were worth $1,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Rise Advisors LLC grew its holdings in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $33,000. Finally, Cape Investment Advisory Inc. lifted its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on JAZZ shares. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Wells Fargo & Company reduced their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Finally, Piper Sandler lowered their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Stock Down 5.7 %

Shares of NASDAQ:JAZZ opened at $109.32 on Wednesday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $143.32. The stock has a market capitalization of $6.89 billion, a price-to-earnings ratio of 22.54, a PEG ratio of 1.45 and a beta of 0.58. The stock has a fifty day simple moving average of $109.69 and a two-hundred day simple moving average of $112.53. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.